# A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.

> **NCT00389298** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 36 (estimated)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** VCH-759 (BCH-27759)

## Key facts

- **NCT ID:** NCT00389298
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2009-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00389298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00389298, "A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00389298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*